Provided by Tiger Trade Technology Pte. Ltd.

Anavex Life Sciences

2.74
-1.4500-34.61%
Post-market: 2.72-0.0200-0.73%18:35 EDT
Volume:14.05M
Turnover:40.37M
Market Cap:253.92M
PE:-5.92
High:3.12
Open:3.01
Low:2.61
Close:4.19
52wk High:13.99
52wk Low:2.61
Shares:92.67M
Float Shares:83.05M
Volume Ratio:8.36
T/O Rate:16.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4626
EPS(LYR):-0.5438
ROE:-33.63%
ROA:-21.56%
PB:2.01
PE(LYR):-5.04

Loading ...

US High Growth Tech Stocks To Watch For Potential Expansion

Simply Wall St.
·
Oct 17, 2025

Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’

GlobeNewswire
·
Oct 10, 2025

Anavex Life Sciences Price Target Maintained With a $42.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 07, 2025

Sector Update: Health Care Stocks Retreat Late Afternoon

MT Newswires Live
·
Oct 03, 2025

BUZZ-Anavex rises after schizophrenia drug meets main goal in study

Reuters
·
Oct 02, 2025

Anavex announces Phase 2 study of ANAVEX3-71 met its primary endpoint

TIPRANKS
·
Oct 02, 2025

Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

GlobeNewswire
·
Oct 02, 2025

Anavex Life Sciences Corp: Anavex3-71-Sz-001 Achieved Its Primary Endpoint

THOMSON REUTERS
·
Oct 02, 2025

Anavex Life Sciences: Secondary and Exploratory Analyses Revealed Encouraging Trends in Several Outcome Measures

THOMSON REUTERS
·
Oct 02, 2025

Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

GlobeNewswire
·
Oct 02, 2025

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Oct 01, 2025

Anavex announces publication on oral blarcamesine Phase IIb/III trial

TIPRANKS
·
Sep 30, 2025

Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial

GlobeNewswire
·
Sep 30, 2025